OpenAI acquires Orchestra Bio to extend Rosalind life-sciences tools
Original title: OpenAI acquires Orchestra Bio
Orchestra’s drug-program agents will join GPT-Rosalind and Rosalind Workbench to coordinate studies and timelines.
OpenAI said it acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development. Orchestra’s team and technology will join Rosalind, OpenAI’s life-sciences models and tools, including GPT-Rosalind and Rosalind Workbench. OpenAI says the combined stack should help scientists connect findings with studies, decisions, and next steps. It also cited existing work with Novo Nordisk and Moderna.
- OpenAI says drug development takes about 10 to 15 years to US approval.
- Orchestra agents track studies and flag how a failed batch can delay a trial.
- The deal is framed as a step toward AI across discovery and development.
- Vendors
- OpenAI
- Organizations
- Novo NordiskModerna
- Countries
- United States
- AI models
- GPT-Rosalind
From the original article
2 min read at openai.com
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
openai.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.